Antithrombin–Factor Xa axis (AT–FXa axis)

The Antithrombin–Factor Xa axis is a fundamental regulatory component of the human coagulation system, centered on the interaction between the endogenous serine protease inhibitor antithrombin (AT) and the procoagulant enzyme Factor Xa (FXa) (StatPearls, 2023). Factor Xa occupies a pivotal position at the convergence of the intrinsic and extrinsic pathways, where it catalyzes the conversion of prothrombin to thrombin, the final effector of clot formation (PubMed, PMID: 11907127). Antithrombin acts as a natural brake on this process by forming a stable, inactive complex with Factor Xa, thereby neutralizing its enzymatic activity. This axis is the primary target for indirect anticoagulants such as unfractionated heparin, low-molecular-weight heparins like enoxaparin, and synthetic pentasaccharides like fondaparinux (NIH, 2022). These agents bind to antithrombin, inducing a conformational change that increases its affinity for Factor Xa by up to 1,000-fold, effectively halting the coagulation cascade (UniProt, P01008). Clinically, modulating this axis is essential for treating and preventing venous thromboembolism, pulmonary embolism, and complications from atrial fibrillation, though it requires careful monitoring to balance antithrombotic efficacy against the risk of hemorrhage (PubChem, CID 62824).

Other names

Antithrombin III–Factor Xa complexATIII–FXa pathwayHeparin–Antithrombin–Factor Xa systemAntithrombin-mediated Factor Xa inhibition

Potentiation of antithrombin-mediated inhibition of Factor Xa through allosteric modulation and/or template mechanisms, accelerating the natural neutralization of the protease.